10-K: Ligand Pharmaceuticals Reports FY 2024 Results, Highlights Royalty Portfolio Growth and Strategic Investments

Ligand Pharmaceuticals' FY 2024 results showcase a 27% revenue increase driven by royalty growth and strategic acquisitions, alongside key investments in pipeline expansion.

Summary

• Ligand Pharmaceuticals Incorporated reported its financial results for the fiscal year ended December 31, 2024.
• The company's revenue increased by 27% to $167.1 million, compared to $131.3 million in 2023, primarily driven by a $23.8 million increase in royalties.
• Royalties from Kyprolis, Rylaze, and Filspari contributed significantly to the revenue, with Filspari showing substantial growth.
• Captisol sales increased by $2.5 million to $30.9 million in 2024.
• The company made several strategic investments, including a royalty financing agreement with Castle Creek Biosciences for $50 million and the acquisition of Apeiron Biologics for $100 million.
• Ligand's operating costs and expenses increased by 56% to $189.7 million, primarily due to higher general and administrative expenses and financial royalty asset impairment.
• The company reported a financial royalty asset impairment of $30.6 million due to Takeda's decision to discontinue the soticlestat program.
• Ligand had $256.2 million in cash, cash equivalents, and short-term investments as of December 31, 2024.
• The company has a $125 million revolving credit facility with Citibank, N.A., with $124.4 million available for borrowing as of December 31, 2024.
• Ligand is focused on expanding its royalty portfolio and leveraging its technology platforms to generate future revenue.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While revenue growth and strategic investments are positive, the increase in operating expenses and financial royalty asset impairment are concerning. The overall outlook is cautiously optimistic.

Positives

• Significant revenue growth driven by royalties and strategic acquisitions.
• Strong performance of key royalty assets like Kyprolis and Filspari.
• Strategic investments in promising late-stage assets and technology platforms.
• Successful acquisition of Apeiron Biologics, adding Qarziba to the royalty portfolio.
• Establishment of royalty financing agreements with Castle Creek Biosciences and Agenus.
• FDA approval and commercial launch of Ohtuvayre, contributing to royalty revenue.
• Successful creation of Pelthos Therapeutics to commercialize ZELSUVMI.
• Remediation of previously identified material weakness in internal control over financial reporting.

Negatives

• Increase in operating costs and expenses, primarily due to higher general and administrative expenses.
• Financial royalty asset impairment of $30.6 million due to Takeda's decision to discontinue the soticlestat program.
• Fair value adjustment to partner program derivatives was $15.1 million for 2024 primarily due to certain Agenus partners discontinuing development of their partnered programs.
• Loss from revaluation of Primrose investments and equity method loss from Primrose Bio.

Risks

• Reliance on third parties for product development and commercialization.
• Potential for lower than expected revenue from key royalty assets.
• Risk of supply chain interruptions affecting Captisol material.
• Competition in acquiring existing passive royalties.
• Limited information about biopharmaceutical products underlying royalties.
• Inaccurate assumptions regarding future cash flow and revenue generation.
• Insolvency of partners or third parties developing products with economic rights.
• Development and regulatory hurdles for product candidates.
• Sales risks associated with biopharmaceutical products.
• Changes in healthcare laws and regulations.
• Difficulties from strategic acquisitions and other M&A transactions.
• Uncertain business operations if a transaction or commercial partnerships involving Pelthos is not consummated.
• Fluctuations in operating results.
• Changes in financial accounting standards or tax laws.
• Limitations on the ability to use net operating loss carryforwards.
• Potential liabilities arising out of state and federal fraudulent conveyance laws.
• Occurrence of a catastrophic disaster.
• Failure, inadequacy, interruption or security lapse of information technology systems.
• Terms of the Credit Agreement may limit flexibility in operating the business.
• Impairment charges pertaining to goodwill, identifiable intangible assets or other long-lived assets.
• Investments are subject to market and credit risks.
• Charter documents and concentration of ownership may hinder or prevent change of control transactions.
• Stock price has been volatile and could experience a sudden decline in value.
• Unfavorable global economic and political conditions.
• Business is subject to risks arising from pandemic and epidemic diseases.
• Securities or industry analysts do not publish research reports about the business or if they make adverse recommendations regarding an investment in the stock.

Future Outlook

Ligand is focused on expanding its royalty portfolio and leveraging its technology platforms to generate future revenue. The Pelthos team is actively preparing for a potential strategic transaction and subsequent commercial launch by mid-2025 of the assets acquired in the Novan acquisition.

Industry Context

Ligand's business model as a biopharmaceutical royalty aggregator differentiates it from traditional biotechnology companies, mitigating risks associated with single-asset development and providing more predictable cash flows. The company's focus on infrastructure-light operations and strategic investments aligns with industry trends towards efficiency and diversification.

Comparison to Industry Standards

• Ligand's royalty-based business model is comparable to companies like Royalty Pharma, which also focuses on acquiring royalty streams from pharmaceutical products.
• Ligand's Captisol technology competes with other drug delivery technologies aimed at improving solubility and stability, such as those developed by companies like CycloLab.
• Ligand's strategic acquisitions and investments are similar to those made by other biopharmaceutical companies seeking to expand their product portfolios and revenue streams, such as Gilead Sciences and Amgen.
• Ligand's focus on late-stage assets is a common strategy in the biopharmaceutical industry to reduce development risk and accelerate time to market, similar to the approach taken by companies like Viking Therapeutics and Travere Therapeutics.

Legal Proceedings

• Ligand is involved in ongoing litigation related to opioid claims and a contract dispute with Bexson Biomedical, Inc.

Stakeholder Impact

• Shareholders may experience fluctuations in stock price due to market conditions and company performance.
• Employees may benefit from company growth and strategic initiatives.
• Customers and patients may gain access to new therapies through Ligand's partnerships and technology platforms.
• Suppliers and creditors may be impacted by Ligand's financial performance and ability to meet obligations.

Next Steps

• Continue to expand the pipeline by aggregating royalty rights in midto late-stage development and commercial biopharma products.
• Actively prepare for a potential strategic transaction and subsequent commercial launch by mid-2025 of the assets acquired in the Novan acquisition (including ZELSUVMI and other assets that may be developed using the NITRICIL technology platform).
• Continue proactive shareholder and employee engagement in 2025.
• Refine EHS policies and practices in 2025.

Key Dates